Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Swiss drug firm Idorsia sells rights to its drug aprocitentan, gets $35M, plans job cuts.

flag Swiss pharmaceutical company Idorsia is in exclusive negotiations to sell global rights to its drug aprocitentan, receiving a $35 million exclusivity fee, which extends its financial runway to 2025. flag The deal may also include additional payments. flag Idorsia plans to streamline operations, potentially cutting about 270 jobs globally, and restructure its debt.

5 months ago
3 Articles

Further Reading